CDKN2A and chordoma: Tissue-based next-generation sequencing (NGS) was performed to evaluate for actionable mutations and returned only a cyclin-dependent kinase inhibitor 2A and 2B (CDKN2A/B) mutation, which is associated with cell cycle dysregulation but currently lacks a targeted therapeutic option in chordoma.